Kura Oncology Reports Q3 Results; KOMZIFTI Revenue Grows 53%, Advances 2027 Pipeline Plans
Kura Oncology (KURA) reported Q3 2026 results with KOMZIFTI revenue up 53% to $13.9M. Net loss narrowed to $70.2M. The company advanced pipeline plans, including studies for AML and solid tumors. Cash reserves totaled $492.1M. Kura also secured $55M in financing from Oberland Capital.
How this was made
The 30-second read
Why it matters
The quarter adds concrete commercial traction (patient starts, prescriptions, revenue), updates collaboration guidance, and extends the funding runway via a sizable Oberland Capital financing, while pushing major clinical milestones into 2027-2028.
Market read
Traders can reassess near-term valuation drivers using fresh KOMZIFTI revenue and commercial metrics, updated collaboration guidance, and the capital-structure implications of the new $300M financing.
What to watch
The $300M financing includes debt and a capped royalty tied to KOMZIFTI net sales, which can cap upside even if sales keep growing; clinical readouts are still back-loaded to 2027-2028.
Background
Kura is commercializing KOMZIFTI (ziftomenib) for R/R NPM1-mutated AML and advancing multiple darlifarnib solid-tumor programs toward planned registrational studies.
Ticker impact
Kura reported Q3 2026 results and KOMZIFTI net product revenue rose 53% sequentially to $13.9M, alongside updated 2026 collaboration guidance.
Shares likely supported as the market prices stronger KOMZIFTI traction and clearer funding into 2027-2028 catalysts.
The article provides fresh, decision-relevant datapoints: revenue growth, cash balance, updated collaboration guidance, and a new $300M strategic financing that affects capital structure and runway.
Market effects
Reinforces demand for commercial-stage menin inhibitor exposure and highlights ongoing AML combination trial execution as a key biotech risk factor.
Limited, primarily impacts US biotech sentiment and small-cap growth risk appetite.
Moderate, as Kyowa Kirin collaboration milestone expectations and FDA alignment can influence broader oncology deal expectations.
Counterpoint
Sequential KOMZIFTI growth may not translate into durable profitability, and collaboration revenue accounting plus non-cash items can mask underlying cash generation.
Key entities
- companyKura Oncology, Inc.
Subject of the article, reporting Q3 2026 results, KOMZIFTI commercial updates, pipeline progress, and a new strategic financing agreement.
- productKOMZIFTI (ziftomenib)
FDA-approved menin inhibitor; article reports 53% sequential revenue growth to $13.9M and increases in patient starts and prescriptions.
- financing_counterpartyOberland Capital affiliates
Provided access to up to $300M via debt and $25M equity, with terms including interest rates and a capped royalty tied to KOMZIFTI net sales.
- collaboration_partnerKyowa Kirin
Collaboration milestone payments totaling $180M are referenced, and collaboration revenue guidance is updated.
- regulatorFDA
Aligned on the design of a planned registrational monotherapy study for darlifarnib in HRAS-mutated salivary gland cancer.
